Abstract CT267: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors
Susanna V. Ulahannan(Oklahoma State University Oklahoma City), Babar Bashir(Thomas Jefferson University), Helen Millward, Desirée Headley, Niall M.B. Martin, Emre Karakoç(University of Washington), Sara Busacca, Sarah V. Holt(Pharma Nord (United Kingdom)), Suraj Menon(AstraZeneca (United Kingdom)), Kathleen N. Moore(University of Oklahoma Medical Center), Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Jason T. Henry(Sarah Cannon Research Institute), Ian C. P. Smith(Royal Marsden Hospital), Nicola Little, Graeme C.M. Smith(Acacia Pharma (United Kingdom)), Elisa Fontana(Sarah Cannon Research Institute), Meredith S. Pelster(Sarah Cannon), Bert H. O’Neil(Indiana University Health)
Cited by 3
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
The DNA-dependent protein kinase
|Genes & Development|1999|884